Matrajt Laura, Eaton Julia, Leung Tiffany, Brown Elizabeth R
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
University of Washington, Tacoma, WA, USA.
Sci Adv. 2021 Feb 3;7(6). doi: 10.1126/sciadv.abf1374. Print 2020 Feb.
Vaccines, when available, will likely become our best tool to control the COVID-19 pandemic. Even in the most optimistic scenarios, vaccine shortages will likely occur. Using an age-stratified mathematical model paired with optimization algorithms, we determined optimal vaccine allocation for four different metrics (deaths, symptomatic infections, and maximum non-ICU and ICU hospitalizations) under many scenarios. We find that a vaccine with effectiveness ≥50% would be enough to substantially mitigate the ongoing pandemic, provided that a high percentage of the population is optimally vaccinated. When minimizing deaths, we find that for low vaccine effectiveness, irrespective of vaccination coverage, it is optimal to allocate vaccine to high-risk (older) age groups first. In contrast, for higher vaccine effectiveness, there is a switch to allocate vaccine to high-transmission (younger) age groups first for high vaccination coverage. While there are other societal and ethical considerations, this work can provide an evidence-based rationale for vaccine prioritization.
疫苗一旦可用,很可能会成为我们控制新冠疫情的最佳工具。即便在最乐观的情况下,疫苗短缺仍可能出现。我们使用一个按年龄分层的数学模型并结合优化算法,确定了在多种情形下针对四种不同指标(死亡、有症状感染以及非重症监护病房和重症监护病房的最大住院人数)的最佳疫苗分配方案。我们发现,一种有效性≥50%的疫苗足以大幅缓解当前的疫情,前提是很大比例的人口得到了最佳接种。在将死亡人数降至最低时,我们发现,对于疫苗有效性较低的情况,无论疫苗接种覆盖率如何,首先将疫苗分配给高风险(年龄较大)年龄组是最优选择。相比之下,对于疫苗有效性较高的情况,在疫苗接种覆盖率较高时,则转而首先将疫苗分配给传播率高(年龄较小)的年龄组。虽然还有其他社会和伦理方面的考虑因素,但这项工作可为疫苗优先排序提供基于证据的理由。